Stock NTII NEUROBIOLOGICAL TECHNOLOGIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Neurobiological Technologies, Inc.

Equities

NTII

US64124W3043

Delayed OTC Markets
Other stock markets
 01:42:05 2024-06-06 pm EDT 		5-day change 1st Jan Change
0.0001 USD +9,900.00% Intraday chart for Neurobiological Technologies, Inc. -.--% +9,900.00%
2012 Neurobiological Technologies Inc. Announces Extraordinary Dividend, Payable on December 27, 2012 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ex-dividend day
FA
Neurobiological Technologies Inc. Announces Extraordinary Dividend, Payable on December 27, 2012
CI
NEUROBIO TECH : Neurobiological Technologies Announces Extraordinary Dividend of $0.18 per Share
PR
NEUROBIO TECH : Neurobiological Technologies Announces Stockholder Approval of Plan of Liquidation and Dissolution
PR
NEUROBIO TECH : Neurobiological Technologies Announces Intent to File Form 25 to Delist Common Stock From the NASDAQ Capital Market
PR
NEUROBIO TECH : Neurobiological Technologies Receives Nasdaq Closing Bid Price Notification
PR
NEUROBIO TECH : Neurobiological Technologies Announces Termination of its License and Cooperation Agreement with Merz and Children's Medical Center
PR
NEUROBIOLO TCHNLGS : Neurobiological Technologies Reports Third Quarter Fiscal 2009 Financial Results
PR
NEUROBIOLO TCHNLGS : Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
PR
NEUROBIOLO TCHNLGS : Neurobiological Technologies Announces Hiring of Advisor to Seek Sale of Company
PR
NEUROBIOLO TCHNLGS : Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results
PR
NEUROBIOLO TCHNLGS : Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
PR
NEUROBIOLO TCHNLGS : Neurobiological Technologies Announces Suspension of Viprinex Development
PR
NEUROBIOLO TCHNLGS : Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis
PR
NEUROBIOLO TCHNLGS : Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
PR
NEUROBIOLO TCHNLGS : Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10
PR
NEUROBIOLO TCHNLGS : Neurobiological Technologies Sets Date for First Quarter Financial Results
PR
NEUROBIOLO TCHNLGS : Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
PR
NEUROBIOLO TCHNLGS : Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
PR
NEUROBIOLO TCHNLGS : Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NTII Stock
  4. News Neurobiological Technologies, Inc.